Literature DB >> 23881518

Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature.

R Giua1, C Pedone, L Cortese, R Antonelli Incalzi.   

Abstract

The multiresistant Acinetobacter species bacteria are frequently involved in urinary or respiratory tract infections, and one of the most effective drugs, colistine, is associated with significant nephrotoxicity and neurotoxicity. Given that very high concentrations of colistine into biological fluids are safe for the human organism, attempts have been made at delivering the drug topically, by aerosol, or, occasionally, intratechally or intraventricularly for meningitis. These topical treatments could eradicate the Pseudomonas sp. from the lung of patients with cystic fibrosis or bronchiectasis and the Acinetobacter baumannii from lung and meninges. However, only one case of colistin topic treatment in urinary tract infection is described. We report a case series of three patients successfully undergone colistin bladder instillations for multi drug resistant Acinetobacter urinary tract infection, and we review the literature about colistin topic treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881518     DOI: 10.1007/s15010-013-0507-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

1.  In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J Li; J Turnidge; R Milne; R L Nation; K Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  A ten year review of colomycin.

Authors:  J M Littlewood; C Koch; P A Lambert; N Høiby; J S Elborn; S P Conway; R Dinwiddie; F Duncan-Skingle
Journal:  Respir Med       Date:  2000-07       Impact factor: 3.415

3.  Bronchoconstriction following nebulised colistin in cystic fibrosis.

Authors:  S Cunningham; A Prasad; L Collyer; S Carr; I B Lynn; C Wallis
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

Review 4.  Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation.

Authors:  C van Nieuwkoop; P L den Exter; H W Elzevier; J den Hartigh; J T van Dissel
Journal:  Int J Antimicrob Agents       Date:  2010-06-26       Impact factor: 5.283

5.  Molecular epidemiology and the clinical significance of Acinetobacter baumannii complex isolated from cerebrospinal fluid in neurosurgical intensive care unit patients.

Authors:  G Bayramoglu; S Kaya; Y Besli; E Cakır; G Can; O Akıneden; F Aydin; I Koksal
Journal:  Infection       Date:  2011-10-29       Impact factor: 3.553

Review 6.  Polymyxin antibiotics: chemical and pharmacokinetic properties.

Authors:  T Bergan; J Fuglesang
Journal:  Antibiot Chemother (1971)       Date:  1982

Review 7.  Diagnosis and management of acute pyelonephritis in adults.

Authors:  Kalyanakrishnan Ramakrishnan; Dewey C Scheid
Journal:  Am Fam Physician       Date:  2005-03-01       Impact factor: 3.292

8.  Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin.

Authors:  Sofia K Kasiakou; Petros I Rafailidis; Konstantinos Liaropoulos; Matthew E Falagas
Journal:  J Infect       Date:  2005-05       Impact factor: 6.072

9.  Antiendotoxin activity of cationic peptide antimicrobial agents.

Authors:  M Gough; R E Hancock; N M Kelly
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

10.  Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.

Authors:  T L Pitt; M Sparrow; M Warner; M Stefanidou
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

View more
  7 in total

1.  Management of urinary tract infection with intravesical amikacin may increase the risk of bladder oxidative stress in children with neurogenic bladder.

Authors:  Akin Soner Amasyali; Dilek Yilmaz; Mustafa Yilmaz; Faruk Kucukdurmaz; Ferah Sonmez; Haluk Erol
Journal:  Int Urol Nephrol       Date:  2017-09-27       Impact factor: 2.370

Review 2.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

3.  Intra-Vesical Colistin for Pseudomonas aeruginosa Urinary Tract Infections.

Authors:  Rui Encarnado Assis; Inês Coelho; André Real; Luís França; Ana Araújo; Tiago Pereira; Nuno Catorze
Journal:  Eur J Case Rep Intern Med       Date:  2019-01-21

Review 4.  Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic Review.

Authors:  Amelia Pietropaolo; Patrick Jones; Mike Moors; Brian Birch; Bhaskar K Somani
Journal:  Curr Urol Rep       Date:  2018-08-09       Impact factor: 3.092

Review 5.  Management of urinary tract infection in women: A practical approach for everyday practice.

Authors:  Nassib F Abou Heidar; Jad A Degheili; Aline A Yacoubian; Raja B Khauli
Journal:  Urol Ann       Date:  2019 Oct-Dec

6.  A Patient Presenting with Cholangitis due to Stenotrophomonas Maltophilia and Pseudomonas Aeruginosa Successfully Treated with Intrabiliary Colistine.

Authors:  Pablo N Pérez; María A Ramírez; José A Fernández; Laura Ladrón de Guevara
Journal:  Infect Dis Rep       Date:  2014-05-13

Review 7.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.